Search contract descriptions, companies and agencies.
GENENTECH OTA - ACTIVATION OF CLIN 0008 FOR ACTEMRA PHASE 3 RCT FOR COVID-19 AND EXTENSION OF CLIN 0005 (LEPB) PERIOD OF PERFORMANCE TO DECEMBER 31, 2021
Total Committed
$25.1M
Product or Service Description
Drugs and Biologicals
Total Potential Value
$576M
Contracting Agency
Effective Date
Sept. 27, 2018
Funding Department
OFFICE OF ACQ&MGMT POLICY
Type
Cost sharing
Solicitation Procedure
Negotiated proposal/quote
Extent Competed
Full and open competition
Recent Contract Actions 
Contracts can have multiple “contract actions”: This is how agencies spend money for a specific purpose, adjust the amount committed or change the contract in a way that doesn’t affect the amount. That last scenario is usually indicated by a $0 action. If there is a contract action for a negative amount, it generally means the contract was adjusted or canceled.
| Vendor | Description | Signed | Reason for Change | Amount Committed |
|---|---|---|---|---|
| GENENTECH, INC. | GENENTECH OTA - ACTIVATION OF CLIN 0008 FOR ACTEMRA PHASE 3 RCT FOR COVID-19 AND EXTENSION OF CLIN 0005 (LEPB) PERIOD OF PERFORMANCE TO DECEMBER 31, 2021 | March 26, 2020 | Supplemental Agreement For Work Within Scope | $25,100,000 |
About this data
This data comes from the Federal Procurement Data System, which includes all contracts worth $10,000 or more. We look at all contracts that are tagged with the procurement code for COVID-19 or otherwise started in 2020 and contain “COVID-19” in the description. Department of Defense contracting data is subject to a 90-day delay before it appears in the data.